/images/ppid_59c68470-image-176433503015011433.webp)
/images/ppid_a911dc6a-image-176420924046465906.webp)
What is the story about?
Neuland Laboratories’ board, on Friday, cleared a capital expenditure of ₹189 crore to set up a new research and development centre in Hyderabad.
The company disclosed the decision to the exchanges after its board meeting on November 28, 2025.
The facility will come up at leased premises in Genome Valley, MN Park, Shamirpet, covering about 1.35 lakh sq. ft. The project is intended to relocate the company’s existing 0.45-lakh-sq-ft R&D unit.
Neuland plans to fund the investment through a mix of borrowings and internal accruals.
The stock gained 4.61% to close at ₹17,340.70, up ₹764.45, on Friday. The company has also recorded a price-earnings ratio above 50 for the last four trailing quarters.
The company disclosed the decision to the exchanges after its board meeting on November 28, 2025.
The facility will come up at leased premises in Genome Valley, MN Park, Shamirpet, covering about 1.35 lakh sq. ft. The project is intended to relocate the company’s existing 0.45-lakh-sq-ft R&D unit.
Neuland plans to fund the investment through a mix of borrowings and internal accruals.
The stock gained 4.61% to close at ₹17,340.70, up ₹764.45, on Friday. The company has also recorded a price-earnings ratio above 50 for the last four trailing quarters.
/images/ppid_a911dc6a-image-176424303920659928.webp)
/images/ppid_59c68470-image-176425005265256491.webp)
/images/ppid_59c68470-image-176421003247534498.webp)
/images/ppid_59c68470-image-176424256634972088.webp)
/images/ppid_59c68470-image-176421753776161216.webp)
/images/ppid_59c68470-image-176430006261388139.webp)